As a new foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply tetraphenylporphyrin from multiple well-known original manufacturers.
As a research-and-development-oriented new foreign trade enterprise, HiSiaddi has repeatedly inspected branded enterprises of tetraphenylporphyrin products through technological transformation cooperation with factories, and conducted multiple rounds of in-depth objective research on different brands. Therefore, we often analyze various domestic tetraphenylporphyrin brands and factories for clients to help them find matching products. The following is a brand recommendation case.
If you need more comparative analysis of brands and models, please contact HiSiaddi customer service.
The buyer, Germany’s LuminaPharma GmbH, is located in the Heidelberg Pharmaceutical Industrial Park in Germany, founded relying on the laboratory of the School of Pharmacy, Heidelberg University. It specializes in R&D and mass production of clinical-grade photodynamic anti-tumor API raw materials and medical fluorescent probes, with products sold to clinical laboratories of Grade A tertiary hospitals in Germany, Austria, Switzerland and other EU countries. Tetraphenylporphyrin (TPP, CAS: 917-23-7) serves as a key intermediate for photosensitive API raw materials, with internal control standards aligned with the European Pharmacopoeia (EP) and German Pharmacopoeia. The client previously purchased stable annual supplies of 2.6kg (1.9kg for mass production feeding + 0.7kg for new drug clinical small trials) of high-purity TPP from Japan’s TCI.
Faced with consecutive price hikes of Japanese and Korean reagents and extended overseas original manufacturer delivery lead times of over 90 days, the client launched a domestic substitution project for raw materials. Unfamiliar with domestic porphyrin industry brand segmentation and product grading rules, the client independently contacted 5 domestic top mid-to-high-end manufacturers: Zhejiang Weihua, Jiangsu Xinnuoke, Xi’an Ruixi, Tianjin Hesiensi and Shanghai Aladdin, requesting sample delivery and quotations from each. Sales staff of all factories complied with industry norms without maliciously belittling competitors, yet only promoted their flagship products, avoiding objective elaboration of competitors’ advantages, applicable scenarios and shortcomings: Weihua prioritized mass-produced pharmaceutical-grade products, Xinnuoke prioritized optoelectronic catalytic grade, Ruixi focused on customized high-purity research-grade products, Hesiensi prioritized subpackaged reagent grade, and Aladdin prioritized laboratory small-specification products.
The client received 7 sample batches from 5 manufacturers. Self-laboratory testing revealed issues including excessive impurities, inconsistent batch stability and solubility mismatches with synthetic formulas. The client spent over 14,000 EUR on sample testing costs yet failed to confirm a supplier brand, putting model selection on hold. Upon recommendation by Germany’s Fine Chemical Industry Association, the client fully entrusted Shanghai HiSiaddi Technology (HiSiaddi) to conduct neutral full-brand evaluation and model screening.
1.
Closed Brand Information; One-Sided Promotion by Manufacturers Lacks Horizontal Comparison Basis Domestic TPP products labeled uniformly as "99% high purity" fall into four categories: pharmaceutical mass-production grade, optoelectronic catalytic grade, research customized high-purity grade and general reagent grade. All 5 manufacturers only explained their product lines without disclosing competitors’ applicable scenarios, leading the client to mistakenly apply catalytic-grade raw materials to clinical probe synthesis, resulting in substandard photosensitive conversion rates after on-machine testing.
2.
3.
Ununified National Standards for Purity Labeling; Widely Divergent Measured Indicators for Products with Identical Labeled Specifications Some manufacturers label purity based on main component content, while others deduct by-products for labeling. For products identically labeled HPLC 99%, chlorin impurity levels range from 0.06% to 1.7%. The client applies German Pharmacopoeia acceptance standards and cannot distinguish labeling loopholes.
4.
5.
Dual Raw Material Demands of the Client Are Generally Matched with Single Models The client has two categories of material usage: stable large-scale industrial production and trace new drug clinical R&D. All manufacturers only quoted their flagship single products, failing to match differentiated indicators by scenario.
6.
7.
Uneven Supporting Compliance Documents German pharmaceutical regulatory filing requires bilingual COA, original HPLC spectra and supporting REACH documents. Inspection documents of different brands follow inconsistent specifications; some manufacturers only provide simple Chinese inspection forms, failing to meet EU filing requirements.
8.
Combined with the client’s rigid indicators: HPLC ≥99.4%, chlorin ≤0.08%, total heavy metal content <3ppm, moisture ≤0.2%, HiSiaddi’s chemical technical team neutrally evaluated the 5 major brands from five dimensions: production process, purity, production capacity, supporting documents and applicable scenarios, without favoring any single manufacturer.
Flagship Models: WH-TPP01 (Pharmaceutical Mass-Production Grade), WH-TPP02 (Ultra-High Purity Refined Grade) Advantages: Thousand-ton green continuous synthetic production lines, strong batch stability for large-batch production, sufficient kg-level spot goods, full-item CNAS laboratory test reports, obvious unit price advantages, suitable for scaled mass production feeding; Shortcomings: High minimum order threshold for ultra-high-purity customized models, sharp unit price surcharges for gram-level small-batch customization, no spot milligram subpackaging.
Flagship Model: XNK-TPP995 (Special Grade for Optoelectronic Catalysis) Advantages: Mature metal coordination modification technology, excellent dispersion performance in organic solvents, specialized in photocatalysis and OLED optoelectronic raw materials; Shortcomings: Internal control upper limit of chlorin at 0.3%, impurity indicators failing to meet medical probe limits, unsuitable for pharmaceutical clinical synthesis.
Flagship Model: RX-TPP-HP (Pharmaceutical Ultra-High Purity Custom Grade) Advantages: Improved low-temperature Lindsey synthetic process with controllable chlorin ≤0.05%, flexible flexible production for small batches, full English/Chinese bilingual COA and SDS complying with EU pharmaceutical regulatory filing specifications, precisely matching new drug small-trial R&D; Shortcomings: Limited mass production capacity for large bulk orders, higher unit prices for bulk procurement, slightly longer lead time for mass production stock preparation.
Flagship Model: HES-TPP General Reagent Grade Advantages: Complete spot small packages from milligram to gram scale, clean subpackaging standards met; Shortcomings: Raw materials purchased as crude products for re-refining, uncontrollable raw material traceability, large fluctuation of inter-batch impurities, insufficient stability for year-round kg-level mass supply, unsuitable for long-term mass production.
Flagship Model: AL-TPP High-Purity Reagent Grade Advantages: Full-specification spot goods, fast domestic logistics, standardized complete compliance documents; Shortcomings: No self-owned synthetic production lines, outsourced OEM production of products, large purity fluctuation for large bulk batches, only suitable for basic university research, failing to meet pharmaceutical factory mass production standards.
Combined with the client’s dual procurement demands of 1.9kg industrialized mass production raw materials and 0.7kg clinical new drug small trials, we comprehensively evaluated purity compliance, supply stability, completeness of compliance documents and long-term cost performance, finally selecting two mid-to-high-end brands (Zhejiang Weihua and Xi’an Ruixi) with three segmented models:
1.
Zhejiang Weihua WH-TPP01 (Pharmaceutical Mass-Production Grade) → 1.9kg Raw Materials for Industrial Mass Production Measured HPLC purity 99.5% and chlorin content 0.065%. Continuous production lines guarantee stable annual scheduling, with supporting full-item CNAS test reports, perfectly matching the client’s conventional scaled production of API raw materials.
2.
3.
Xi’an Ruixi RX-TPP-HP (Ultra-High Purity Custom Type I) → 0.4kg Raw Materials for High-Activity New Drug Small Trials Chlorin ≤0.045%, heavy metals <2ppm, adjustable impurity indicators on demand, with bilingual quality inspection documents directly usable for German pharmaceutical regulatory filing.
4.
5.
Xi’an Ruixi RX-TPP-HP-Modified (Ultra-High Purity Custom Type II) → 0.3kg Raw Materials for Targeted Derivative R&D Adjusted phenyl impurity control standards based on the basic high-purity grade, matching the client’s synthetic formula for new porphyrin derivatives.
6.
1. Samples of all three models passed full physical, chemical and photosensitive performance testing by the client’s German laboratory, with all indicators meeting German Pharmacopoeia standards. A long-term procurement framework for annual 2.6kg was signed within the same month for batch delivery by quarter.
2. Supported by this successful domestic model selection, the client cut comprehensive raw material procurement costs by 32% compared with original Japanese TCI supplies, and lead time was shortened from 90 days to 22 days, enabling smooth and on-time progress of new drug pilot projects.
3. The German pharmaceutical enterprise subsequently entrusted HiSiaddi with annual pre-indicator review of new batches and pre-audit of compliance documents. Supported by this case, HiSiaddi connected two equivalent European pharmaceutical enterprises in the Netherlands and Austria to complete domestic porphyrin model selection.
Domestic porphyrin manufacturers focus on their own niche sectors and lack willingness to provide cross-brand horizontal recommendations. Overseas mid-to-high-end pharmaceutical clients are constrained by strict local pharmacopoeia standards and lack the capability to screen domestic raw material information. As a neutral third party, HiSiaddi breaks information barriers among manufacturers and conducts layered model selection based on clients’ actual application scenarios, avoiding losses from incorrect procurement while assisting overseas clients to achieve stable delivery of domestic high-end raw materials.
If you need more comparative analysis of brands and models, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
